The cognitive impact of antiepileptic drugs
- PMID: 22164192
- PMCID: PMC3229254
- DOI: 10.1177/1756285611417920
The cognitive impact of antiepileptic drugs
Abstract
Effective treatment of epilepsy depends on medication compliance across a lifetime, and studies indicate that drug tolerability is a significant limiting factor in medication maintenance. Available antiepileptic drugs (AEDs) have the potential to exert detrimental effects on cognitive function and therefore compromise patient wellbeing. On the other hand, some agents may serve to enhance cognitive function. In this review paper, we highlight the range of effects on cognition linked to a variety of newer and older AEDs, encompassing key alterations in both specific executive abilities and broader neuropsychological functions. Importantly, the data reviewed suggest that the effects exerted by an AED could vary depending on both patient characteristics and drug-related variables. However, there are considerable difficulties in evaluating the available evidence. Many studies have failed to investigate the influence of patient and treatment variables on cognitive functioning. Other difficulties include variation across studies in relation to design, treatment group and assessment tools, poor reporting of methodology and poor specification of the cognitive abilities assessed. Focused and rigorous experimental designs including a range of cognitive measures assessing more precisely defined abilities are needed to fill the gaps in our knowledge and follow up reported patterns in the literature. Longitudinal studies are needed to improve our understanding of the influence of factors such as age, tolerance and the stability of cognitive effects. Future trials comparing the effects of commonly prescribed agents across patient subgroups will offer critical insight into the role of patient characteristics in determining the cognitive impact of particular AEDs.
Keywords: antiepileptic drugs; cognition; epilepsy; medication; neuropsychology; seizure.
Conflict of interest statement
The authors declare no conflicts of interest in preparing this article.
References
-
- Aikiä M., Jutila L., Salmenperä T., Mervaala E., Kälviäinen R. (2006) Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy. Epilepsy Behav 8: 750–755 - PubMed
-
- Aikiä M., Kälviäinen R., Sivenius J., Halonen T., Riekkinen P.J. (1992) Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 11: 199–203 - PubMed
-
- Aldenkamp A.P., Alpherts W.C., Moerland M.C., Ottevanger N., Van Parys J.A. (1987) Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 28: 507–514 - PubMed
-
- Aldenkamp A.P., Alpherts W.C.J., Diepman L., Vantslot B., Overweg J., Vermeulen J. (1994) Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization related epilepsy. Epilepsy Res 19: 37–43 - PubMed
-
- Aldenkamp A.P., Baker G., Mulder O.G., Chadwick D., Cooper P., Doelman J., et al. (2000) A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41: 1167–1178 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
